-
Product Insights
NewNet Present Value Model: Everest Medicines Ltd’s SPR-206
Empower your strategies with our Net Present Value Model: Everest Medicines Ltd's SPR-206 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Agenus Inc’s Botensilimab
Empower your strategies with our Net Present Value Model: Agenus Inc's Botensilimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPR-206 in Enterobacteriaceae Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPR-206 in Enterobacteriaceae Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SPR-206 in Enterobacteriaceae Infections Drug Details:SPR-206 is under develoment for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPR-206 in Acinetobacter Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPR-206 in Acinetobacter Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SPR-206 in Acinetobacter InfectionsDrug Details:SPR-206 is under develoment for the treatment of gram-negative...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPR-206 in Pseudomonas aeruginosa Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPR-206 in Pseudomonas aeruginosa Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SPR-206 in Pseudomonas aeruginosa Infections Drug Details:SPR-206 is under develoment for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Survodutide in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Survodutide in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Survodutide in Obesity Drug Details: BI-456906 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Esophageal Squamous Cell Carcinoma (ESCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tildacerfont in Polycystic Ovarian Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tildacerfont in Polycystic Ovarian Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tildacerfont in Polycystic Ovarian Syndrome Drug Details: Tildacerfont (SPR-001) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NCE-401 in Bile Duct Cancer (Cholangiocarcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NCE-401 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: NCE-401 (TU-2218, SKI-2218) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upleganan in Acinetobacter Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upleganan in Acinetobacter Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upleganan in Acinetobacter Infections Drug Details: SPR-206 is under develoment for...